Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Adil E. Wakil is active.

Publication


Featured researches published by Adil E. Wakil.


Journal of Clinical Investigation | 2013

Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B

Anuj Gaggar; Stephen L. Nishimura; Christine M. Van Horn; Amanda Goodsell; Marcus O. Muench; R. Lee Reinhardt; Nico van Rooijen; Adil E. Wakil; Marion G. Peters; Jason G. Cyster; David J. Erle; Philip J. Rosenthal; Stewart Cooper; Jody L. Baron

Hepatitis B virus (HBV) is a major human pathogen that causes immune-mediated hepatitis. Successful immunity to HBV is age dependent: viral clearance occurs in most adults, whereas neonates and young children usually develop chronic infection. Using a mouse model of HBV infection, we sought mechanisms underpinning the age-dependent outcome of HBV and demonstrated that hepatic macrophages facilitate lymphoid organization and immune priming within the adult liver and promote successful immunity. In contrast, lymphoid organization and immune priming was greatly diminished in the livers of young mice, and of macrophage-depleted adult mice, leading to abrogated HBV immunity. Furthermore, we found that CXCL13, which is involved in B lymphocyte trafficking and lymphoid architecture and development, is expressed in an age-dependent manner in both adult mouse and human hepatic macrophages and plays an integral role in facilitating an effective immune response against HBV. Taken together, these results identify some of the immunological mechanisms necessary for effective control of HBV.


American Journal of Transplantation | 2003

De Novo Non‐Alcoholic Fatty Liver Disease Following Orthotopic Liver Transplantation

Fred Poordad; Robert G. Gish; Adil E. Wakil; Richard Garcia-Kennedy; Paul Martin; Francis Y. Yao

Non‐alcoholic fatty liver disease (NAFLD) is an increasingly recognized clinico‐pathologic entity typically associated with obesity, type II diabetes and hyperlipidemia. It has been noted to recur after orthotopic liver transplantation (OLT). We report four patients who developed de novo NAFLD within 3 months of OLT without the typical predisposing factors of diabetes mellitus or obesity. Three of the four patients underwent OLT for hepatitis C‐related cirrhosis, and the other for alcoholic cirrhosis. Examination of the liver explants revealed no evidence of steatosis. No surreptitious alcohol use or a drug‐induced process could be identified in these patients. Treatment of recurrent hepatitis C infection in one patient with interferon and ribavirin led to sustained suppression of the viral RNA to undetectable levels, but no improvement in histology or liver enzymes. All four patients had histologic evidence of preservation injury on the initial post‐OLT biopsies, but the significance of this finding in relationship to the development of NAFLD is unknown. NAFLD can develop without any of the known predisposing conditions after transplantation, and this raises further questions about the pathogenesis of this condition.


Science Translational Medicine | 2018

An OX40/OX40L interaction directs successful immunity to hepatitis B virus

Anuj Gaggar; Jillian M. Jespersen; Ugur Halac; Audra J. Johnson; Amanda Goodsell; Lia Avanesyan; Stephen L. Nishimura; Meghan Holdorf; Keith Mansfield; Joyce Judge; Arya Koshti; Michael Croft; Adil E. Wakil; Philip J. Rosenthal; Eric Pai; Stewart Cooper; Jody L. Baron

Effective immunity and therapeutic targets are identified with a model of hepatitis B virus clearance and persistence. Hepatitis immunity: Better with age Hepatitis B virus (HBV) infection can have severe complications, including cirrhosis and cancer. Most chronic HBV patients are infected at an early age, as adults can readily clear the virus. Publicover et al. used a mouse model of age-dependent HBV clearance and samples from patients to study the mechanisms leading to effective immunity in adults. They discovered that OX40 ligand expression in hepatic immune cells increases with age and is important for viral control. These results clarify some of the chronological differences in the immune response and also suggest that boosting OX40 activity in infants and chronically-infected adults could promote effective HBV immunity. Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.


Immunogenetics | 2012

KIR genotypic diversity can track ancestries in heterogeneous populations: a potential confounder for disease association studies.

Komal Manpreet Singh; Yume T. Phung; Mohamed Kohla; Billy Y-A Lan; Sharon Chan; Diana L. Suen; Sahar Murad; Shana Rheault; Peter J. Davidson; Jennifer L. Evans; Manpreet Singh; Sofie Dohil; Robert W. Osorio; Adil E. Wakil; Kimberly Page; Sandy Feng; Stewart Cooper

Killer cell immunoglobulin-like receptors (KIR) are encoded by highly polymorphic genes that regulate the activation of natural killer (NK) cells and other lymphocyte subsets and likely play key roles in innate and adaptive immunity. Association studies increasingly implicate KIR in disease predisposition and outcome but could be confounded by unknown KIR genetic structure in heterogeneous populations. To examine this, we characterized the diversity of 16 KIR genes in 712 Northern Californians (NC) stratified by self-assigned ethnicities and compared the profiles of KIR polymorphism with other US and global populations using a reference database. Sixty-eight distinct KIR genotypes were characterized: 58 in 457 Caucasians (NCC), 17 in 47 African Americans (NCAA), 21 in 80 Asians (NCA), 20 in 74 Hispanics (NCH), and 18 in 54 “other” ethnicities (NCO). KIR genotype patterns and frequencies in the 4 defined ethnicities were compared with each other and with 34 global populations by phylogenetic analysis. Although there were no population-specific genotypes, the KIR genotype frequency patterns faithfully traced the ancestry of NCC, NCAA, and NCA but not of NCH whose ancestries are known to be more heterogeneous. KIR genotype frequencies can therefore track ethnic ancestries in modern urban populations. Our data emphasize the importance of selecting ethnically matched controls in KIR-based studies to avert spurious associations.


Hepatology | 2016

Liver capsule: Age‐influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man

Jillian M. Jespersen; Audra J. Johnson; Stephen L. Nishimura; Amanda Goodsell; Adil E. Wakil; Philip J. Rosenthal; Eric Pai; Lia Avanesyan; Stewart Cooper; Jody L. Baron

eren es 1. P ubover, ., G oosell A , N ihim ra S , V ilainho S , W ng Z e, A vaesyan L, et l. I-21 is potal in dterm iing age-pendent effeiveness of im m ne reonse in a m ouse m odel of um an heatitis B . J C lin Inest 2011;11154-1162. 2. P ubcover J, G agar A , N ihim ra S , V an H rn C M , G oosell A , M unch M O , et l. A ge-dendent hpatic ym poid orgization dects sucessful im m unity to heatitis B . J C lin Inest 2013;13728-3739. R ecived July 1, 215; acep ed O ctob er 6, 215. D O I 10.02/hep .2284 P otntial confl ct of inrest: D r. R osnthal ad vses nd reeived g rnts fom G iad . H e cosults or A b b V ie nd R erop hin. H e reeived g rnts fom B ritol-M yers S q ib b nd G enntech C op rig ht


Science | 1998

Requirement for IL-13 Independently of IL-4 in Experimental Asthma

Gabriele Grünig; Martha L. Warnock; Adil E. Wakil; Rajeev Venkayya; Frank Brombacher; Donna Rennick; Dean Sheppard; Markus Mohrs; Debra D. Donaldson; Richard M. Locksley; David B. Corry


Clinical Gastroenterology and Hepatology | 2007

Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.

Ira Yu; Atoya Adams; Robert G. Gish; Adil E. Wakil; Natalie Bzowej; R. Todd Frederick; Maurizio Bonacini


Journal of Virological Methods | 2004

Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler™ real-time PCR

Madhu Singh; Annie Dicaire; Adil E. Wakil; Carolyn Luscombe; Stephen L. Sacks


Archive | 2007

ORIGINAL ARTICLES—LIVER, PANCREAS AND BILIARY TRACT Mycophenolate Mofetil in Autoimmune Hepatitis Patients Not Responsive or Intolerant to Standard Immunosuppressive Therapy

Atoya Adams; Robert G. Gish; Adil E. Wakil; Natalie Bzowej; R. Todd Frederick; Maurizio Bonacini


Methods in molecular medicine | 2004

Hepatitis B in Liver Transplant Recipients as a Special Model of Antiviral Drug Development

Robert G. Gish; Adil E. Wakil

Collaboration


Dive into the Adil E. Wakil's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stewart Cooper

California Pacific Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jody L. Baron

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anuj Gaggar

University of California

View shared research outputs
Top Co-Authors

Avatar

Atoya Adams

California Pacific Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David B. Corry

Baylor College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge